Skip to main content Accessibility help
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • 47 - Blood Product Transfusions

  • from Subsection 4F - Clinical – Hematologic
  • Edited by Sharon E. Mace, Cleveland Clinic Lerner College of Medicine, Ohio
  • Book:
    Observation Medicine
    Published online:
    27 June 2025
    Print publication:
    26 June 2025, pp 283-288

  • Summary

    Hemodynamically stable patients needing transfusions are appropriate for placement in an observation unit. Transfusions of red blood cells (RBCs), platelets, and platelet products: fresh frozen plasma (FFP), cryoprecipitate, and factors including von Willebrand factor (vWF), and factors VIII and IX, can be done in selected patients in the observation unit (OU). Administration of drugs such as DDAVP and TXA (tranexamic acid) can be used to treat bleeding. Patients with anemia, sickle cell disease, hemophilia, and von Willebrand’s disease are among those patients with hematologic and/or bleeding disorders who, if stable, might be treated in an OU instead of as an inpatient. In the OU, transfusions can be given over hours when indicated and patients can be monitored for transfusion reactions.